Quinoline and quinazoline compounds useful in therapy
CA 2236239 C · Owner: Pfizer Limited · Inventors: Fox, David Nathan Abraham; Collis, Alan John
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula I, (see fig. I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents an aryl group or a heteroaryl group optionally substituted by C1-4 alkyl or SO2NH2;, R3 represents a 4-, 5-, 6-. or 7-membered heterocyclic ring containing at least one heteroatom selected from N. O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from N O, and S, the ring system as a whole being optionally substituted; X represents CH or N: and, L is absent or represents a cyclic group of formula Ia. (see fig.Ia) or represents a chain of formula Ib, (see fig.Ib) …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 29, 1998 and granted March 18, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 29, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 29, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.